Autophagy inhibition using hydrochloroquine in breast cancer patients: a pilot study

Autophagy inhibition using hydrochloroquine in breast cancer patients: a pilot study - HCQ TRIAL

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON34049

Enrollment

Registered

2010-10-26

Start date

2011-01-03

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

800 mg once, and then 400 mg/day HCQ for 2 to 3 weeks until surgery.

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: •Patients with core-biopsy proven invasive adenocarcinoma of the breast •Any tumor with a size >= 1cm (NOT inflammatory breast cancer) •WHO-performance score 0 or 1 •Written informed consent

Exclusion criteria

Exclusion criteria: •Any psychological, familial, sociological or geographical condition potentially hampering adequate informed consent or compliance with the study protocol •Hampered liver or kidney function •Serious gastro-intestinal disease •Neurological disease (including epilepsy) •Hematological disease •Psoriasis •Porphyry •G6PD deficiency •Hypersensitivity for quinine •Use of gold containing drugs, oxyfenbutazone, fenylbutazone, digoxin •Operation for breast cancer foreseen within 14 days after inclusion in the study.

Design outcomes

Primary

Measure	Time frame
-	—

Secondary

Measure	Time frame
-	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)